Compare Microsoft (MSFT) vs Novo Nordisk A/S (NVO) Price & Performance

MicrosoftTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Microsoft vs Novo Nordisk A/S — how do they compare? Microsoft trades at $499.61 (market cap $3.74T), while Novo Nordisk A/S trades at $45.88 (market cap $207.85B). The key difference: Microsoft is far larger — about 18× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

	MSFT	NVO
Market Cap	$3.74T	$207.85B
Volume	36,654,621	—
Sector	Technology	Health
52-Week High	$542.07	$63.98
52-Week Low	$352.83	$35.29
Enterprise Value	$3.72T	$222.55B
Dividend Yield	0.72%	3.81%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Microsoft

Microsoft (MSFT) trades at $506.06, up 1.21% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Analyst consensus remains overwhelmingly positive with 80.49% buy ratings and $552.73 price target, representing 9.2% upside potential. Recent news highlights Microsoft's AI leadership and cloud computing strength.

Microsoft presents a compelling investment case with strong financial performance and AI-driven growth prospects. Key opportunities include Azure cloud expansion and Copilot adoption, while risks involve increased capital expenditures and competitive pressures. The stock's current valuation at 28.19 P/E appears reasonable given growth trajectory, though investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.

Novo Nordisk A/S

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSFT

Microsoft stock jumps 20%, but high valuation limits further upside, says investor.Seeking Alpha · 17 hours agoBearish Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 22 hours agoNeutral Microsoft remains a Buy after 31% rally, driven by strong Azure growth and AI investments.Seeking Alpha · 1 day agoBullish View details →

NVO

Novo Nordisk downgraded to Sell on weak growth and operational issues despite strong semaglutide sales.Seeking Alpha · 4 days agoBearish View details →

About Microsoft

Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.